We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
101
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.97M 0.11%
65,490
-56,900
-46% -$3.68M
BPMC
102
DELISTED
Blueprint Medicines
BPMC
$2.97M 0.11%
+67,710
New +$3.25M
WELL icon
103
Welltower
WELL
$168B
$2.72M 0.1%
41,484
– –
BCYC
104
Bicycle Therapeutics
BCYC
$270M
$2.62M 0.1%
88,676
– –
DOC
105
DELISTED
PHYSICIANS REALTY TRUST
DOC
$2.44M 0.09%
168,741
– –
IDYA icon
106
IDEAYA Biosciences
IDYA
$3.41B
$2.42M 0.09%
133,185
– –
CSII
107
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.38M 0.09%
174,859
– –
GTHX
108
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.3M 0.09%
423,869
– –
CRSP icon
109
CRISPR Therapeutics
CRSP
$4.88B
$2.24M 0.08%
55,080
– –
RCM
110
DELISTED
R1 RCM Inc. Common Stock
RCM
$2.22M 0.08%
202,351
– –
ARQT icon
111
Arcutis Biotherapeutics
ARQT
$3.24B
$2.2M 0.08%
148,874
– –
MEDP icon
112
Medpace
MEDP
$16B
$2M 0.08%
9,435
– –
NTRA icon
113
Natera
NTRA
$38.7B
$1.98M 0.07%
49,272
+27,872
+130% +$1.15M
OPCH icon
114
Option Care Health
OPCH
$3.55B
$1.96M 0.07%
64,975
– –
ICLR icon
115
Icon
ICLR
$12.2B
$1.81M 0.07%
9,334
-1,100
-11% -$218K
ASRT
116
DELISTED
Assertio
ASRT
$1.77M 0.07%
27,372
– –
PRGO icon
117
Perrigo
PRGO
$1.48B
$1.75M 0.07%
51,224
– –
EWTX icon
118
Edgewise Therapeutics
EWTX
$4.13B
$1.74M 0.07%
195,025
– –
XRN
119
Chiron Real Estate Inc
XRN
$511M
$1.66M 0.06%
34,979
– –
PHG icon
120
Philips
PHG
$25.6B
$1.65M 0.06%
128,302
-64,152
-33% -$774K
TAK icon
121
Takeda Pharmaceutical
TAK
$53.7B
$1.64M 0.06%
105,073
– –
ARDX icon
122
Ardelyx
ARDX
$1.23B
$1.54M 0.06%
539,408
– –
ARVN icon
123
Arvinas
ARVN
$520M
$1.47M 0.06%
42,998
-42,999
-50% -$1.81M
GSK icon
124
GSK
GSK
$103B
$1.47M 0.06%
41,852
– –
MRUS
125
DELISTED
Merus
MRUS
$1.43M 0.05%
92,325
-76,882
-45% -$1.35M
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.